Pfizer-BioNTech COVID-19 Vaccine

2 doses 21 days apart

The Pfizer-BioNTech vaccine was 95% effective in preventing laboratory-confirmed COVID-19 cases in people with no evidence of prior infections.

How to Clean and Disinfect Your Home if Someone has COVID-19

General information

Name: BNT162b2
Manufacturer: Pfizer, Inc., and BioNTech
Vaccine type: mRNA
Number of doses: 2 doses 21 days apart
Mode of administration: injection into the muscle of the upper arm
Does not contain: Eggs, Preservatives, Latex.

Who should get vaccinated?

The Pfizer-BioNTech vaccine is recommended for people 16 years of age and older. Learn more about the CDC's recommendation process for the COVID-19 vaccine and who should get vaccinated sooner if supplies are limited.


Who should not get vaccinated?

If you have had a severe allergic reaction, also known as anaphylaxis, to any of the ingredients in the Pfizer-BioNTech vaccine, you should not get vaccinated. * Learn more about COVID-19 vaccines and rare severe allergic reactions.
* If you have had a severe allergic reaction to other vaccines or injectable therapies, ask your doctor if you should receive the Pfizer-BioNTech vaccine. Your doctor will help you determine if it is safe to receive the Pfizer-BioNTech vaccine.


Side effects and safety

In the arm where you received the injectable vaccine:

  • Pain
  • Swelling
  • Redness

In the rest of the body:

  • Shaking chills
  • Fatigue
  • Headache

These side effects usually appear within a day or two after getting vaccinated. They can look like flu symptoms and may even affect your ability to do daily activities, but they should go away in a few days.

Information on the effectiveness of the vaccine

Based on evidence from clinical trials, the Pfizer-BioNTech vaccine was 95% effective in preventing laboratory-confirmed COVID-19 cases in people with no evidence of prior infections.
CDC will continue to provide updates as more information becomes available about the effectiveness of the Pfizer-BioNTech vaccine under real-world conditions.

Demographic information from clinical trials

The Phase 2 and Phase 3 clinical trials for the Pfizer-BioNTech vaccine included people from the following racial and ethnic categories:

  • 81,9 % white
  • 26,2 % Hispanic/Latina
  • 9,8 % African American
  • 4,4 % Asian
  • < 3 % of people of other races / ethnicities

Breakdown by age and sex:

  • 50,6 % men
  • 49,4 % women
  • 21,4 % 65 years of age or older​

The most common underlying conditions were obesity (35.1%), diabetes (8.4%), and lung disease (7.8%).

Top